Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-08-02 Delisting Announcement
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs
Delisting Announcement Classification · 100% confidence The document explicitly announces the company's intention to delist its American Depositary Shares (ADS) from the Nasdaq Capital Market and terminate its SEC reporting obligations. The text details the timeline for filing Form 25 and Form 15F, which are standard procedures for a delisting process. This fits the definition of a Delisting Announcement (DLST).
2019-08-02 English
Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs
Delisting Announcement Classification · 100% confidence The document explicitly announces the company's intention to delist its American Depositary Shares (ADS) from the Nasdaq Capital Market and terminate its SEC reporting obligations. The text details the timeline for filing Form 25 and Form 15F, which are standard procedures for a delisting process. This fits the definition of a Delisting Announcement (DLST).
2019-08-02 English
Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs
Delisting Announcement Classification · 99% confidence The document explicitly states that Oasmia Pharmaceutical AB 'intends to delist its American Depositary Shares (ADS) from the Nasdaq Capital Market (NASDAQ) and to deregister and terminate its reporting obligations with the Securities and Exchange Commission (SEC).' It mentions filing Form 25 and subsequently Form 15F. This content directly relates to the cessation of trading on an exchange and the termination of SEC reporting requirements, which aligns perfectly with the definition of a Delisting Announcement (DLST). The document length is short (2974 chars) and serves as an official notice of this corporate action.
2019-08-02 English
New number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 100% confidence The document announces an increase in the number of shares and votes in Oasmia Pharmaceutical AB due to the exercise of warrants. This is a direct announcement of a change in the company's capital structure (share count and share capital). According to the provided definitions, an announcement regarding new share issues or capital changes falls under the 'SHA' category.
2019-07-31 English
New number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 100% confidence The document announces an increase in the number of shares and votes in Oasmia Pharmaceutical AB due to the exercise of warrants. This is a direct announcement of a change in the company's capital structure (share count and share capital). According to the provided definitions, an announcement regarding new share issues or capital changes falls under the 'SHA' category.
2019-07-31 English
New number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 100% confidence The document announces an increase in the number of shares and votes in Oasmia Pharmaceutical AB due to the exercise of warrants. This is a direct announcement of a change in the company's capital structure (share count and share capital). According to the provided definitions, an announcement regarding new share issues or capital changes falls under the 'SHA' category.
2019-07-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.